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ABSTRACT 
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart 
failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. 
The effects of sacubitril/valsartan (LCZ696), a dual-action angiotensin receptor blocker (ARB) and 
neprilysin inhibitor, on arterial stiffness and LV remodelling have not been investigated. 
Methods and Results: This was a randomised, multi-centre, double-blind, double-dummy, active-
controlled, parallel group, study to compare the effects on cardiovascular remodelling of 
sacubitril/valsartan with those of olmesartan in patients with hypertension and elevated pulse 
pressure. MRI scans were used to assess LV mass and local aortic distensibility, at baseline and at 12 
and 52 weeks after initiation of treatment. Central pulse and systolic pressure were determined 
using a SphymoCor® XCEL device at each time point. A total of 114 patients were included, with 57 in 
each treatment group. The mean age was 59.8 years, and 67.5% were male. Demographic 
characteristics did not vary between the two sets of patients. LV mass index decreased to a greater 
extent in the sacubitril/valsartan group compared to the olmesartan group from baseline to 12 
weeks (−6.36 vs. −2.32 g/m2; p = 0.039) and from baseline to 52 weeks (−6.83 vs. −3.55 g/m2; p = 
0.029). These differences remained significant after adjustment for SBP at follow-up (p = 0.036 and 
0.019 at 12 and 52 weeks, respectively) and similar signals (though formally non-significant) were 
observed after adjusting for changes in SBP (p=0.0612 and p=0.0529, respectively). There were no 
significant differences in local distensibility changes from baseline to 12 or 52 weeks between the 
two groups; however, there was a larger reduction in central pulse pressure for the 
sacubitril/valsartan group compared to the olmesartan group (p=0.010).  
Conclusions: Since LV mass change correlates with cardiovascular prognosis, the greater reductions 
in LV mass indicate valuable advantages of sacubitril/valsartan compared to olmesartan. The finding 
that LV mass index decrease might be to some extent independent of systolic BP suggests that the 
effect of the dual-acting agent may go beyond those due to its BP-lowering ability.  
 
KEYWORDS: hypertension, arterial stiffness, heart failure, left ventricular hypertrophy, angiotensin, 
neprilysin 
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INTRODUCTION 
Cardiovascular (CV) remodelling is a gradual process that progresses with age and is accelerated in 
the presence of hypertension 1. There are a number of contributory factors, including decreasing 
elastin content of the artery wall, increased collagen deposition, endothelial dysfunction, and 
alterations in smooth muscle tone 2. The loss of artery elasticity results in increased systolic blood 
pressure (SBP) with little change in diastolic blood pressure (DBP), leading to increased pulse 
pressure (PP). This process results in increased cardiac afterload, leading to left ventricular (LV) 
remodelling followed by LV hypertrophy. Both arterial stiffening and increased LV mass have been 
associated with increased CV risk in community-based cohorts 3-7 and patients with essential 
hypertension 8-10, and are therefore important treatment targets.  
Treatment-induced decreases in BP have been shown to indirectly reduce arterial stiffness and LV 
mass by lowering stress applied to the blood vessel wall and the heart, respectively, diminishing the 
extent of CV remodelling 11. On the other hand, certain antihypertensive agents have demonstrated 
efficacy that goes beyond BP reduction 12-14. Drugs that inhibit the renin–angiotensin system (RAS) 
have been shown to be particularly effective 14. Such agents disrupt angiotensin-II-mediated 
signalling pathways, decreasing extracellular matrix remodelling, endothelial dysfunction, and 
inflammation 11, 15. In addition, similar changes to the more peripheral arteries result in decreased 
pulse wave reflection, leading to a lesser augmentation of central PP at the aorta 11. Both 
angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been 
shown to reduce vascular and LV remodelling, and cause reduction of LV hypertrophy, in patients 
with hypertension or CV disease 13, 14, 16-19. 
A further target for BP reduction is the endopeptidase, neprilysin. Inhibition of this species increases 
bioavailability of natriuretic peptides, promoting vasodilation and reducing ventricular remodelling 
20. However, agents that inhibit neprilysin also increase the formation of vasoconstrictory species, 
such as angiotensin II and endothelin 21, 22. Evaluation of the neprilysin inhibitor, candoxatril, 
demonstrated disappointing antihypertensive effects, leading to discontinuation of its development 
23. Dual inhibition of neprilysin and ACE with the agent omapatrilat provided SBP and PP lowering 
along with decreased stiffness, which was superior to that achieved with the ACE-inhibitor, enalapril, 
alone 24. However, the unacceptable rate of angioedema thwarted its approval. Sacubitril/valsartan, 
a more recently developed drug, disrupts angiotensin II signalling through blockade of the AT1 
receptor, and inhibits neprilysin through the non-peptidic AHU377 moiety 20, 25. In patients with heart 
failure with a reduced ejection fraction, the agent was found to significantly reduce the risk of the 
composite endpoint of CV death or heart failure hospitalisation, CV death and death from any cause 
in comparison to enalapril 26. Sacubitril/valsartan is presently approved in more than 60 countries 
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worldwide and is indicated to reduce the risk of CV death and hospitalisation for patients with 
chronic heart failure with a reduced ejection fraction. To further understand the effects of 
sacubitril/valsartan on the LV and large arteries the present study evaluated the effects of 
sacubitril/valsartan compared to the ARB, olmesartan, on cardiovascular remodelling in patients with 
hypertension. 
 
METHODS 
Study design  
This was a multi-centre randomised, multi-centre, double-blind, double-dummy, active-controlled, 
parallel group study to compare the effects on cardiovascular remodelling of sacubitril/valsartan with 
those of olmesartan in patients with hypertension and elevated PP (Clinicaltrials.gov, NCT01870739). 
The study comprised a screening period followed by a 4-week washout period, where eligible 
patients stopped using any anti-hypertensive medication (Figure 1). During these 4 weeks, patients 
received both a placebo to sacubitril/valsartan and a placebo to olmesartan in order to evaluate 
treatment compliance. The patients subsequently underwent a cardiac and aortic MRI scan (3.0 
Tesla), had SphygmoCor® XCEL measurements taken, and provided blood samples. The 
cardiovascular MRI images were sent to an academic imaging core laboratory for quality control. 
Upon verification that the scans were evaluable, patients were randomised 1:1 to sacubitril/valsartan 
or olmesartan by using consecutive ascending randomization numbers in the treatment blocks 
allocated to each study site. The randomization was stratified by presence or absence of statin and 
oral antidiabetic therapy. The randomization list was produced using an automated random number 
generator.  
During the first 2 weeks of the drug treatment period, patients received sacubitril/valsartan 200 mg 
q.d. (tablet) plus a placebo to olmesartan (capsule), or olmesartan 20 mg q.d. (capsule) plus a 
placebo to sacubitril/valsartan (tablet). The dosages were then force-titrated to maintenance doses 
of sacubitril/valsartan 400 mg q.d. or olmesartan 40 mg q.d., which were taken for the subsequent 
10 weeks. After this time, amlodipine could be added to the therapy (add-on period) if deemed 
necessary for achieving adequate BP control. No dose adjustments of sacubitril/valsartan or 
olmesartan, or interruptions, were permitted. 
Patient compliance was evaluated by the counting of pills by a physician at selected time-points. In 
addition, patients were provided with individual diary cards to record administration of the study 
medication on a daily basis. These cards were checked regularly by site staff. 
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The study was approved by the local ethics committee at each trial center, and was conducted in 
accordance with the Declaration of Helsinki and its amendments. All included patients provided 
written informed consent. 
 
Patients 
Included individuals were ≥18 years of age and had essential hypertension stage 1 and 2 (mean 
seated [ms] SBP ≥140 mmHg and <180 mmHg) 8 and elevated brachial PP (≥50 mmHg) 27. Patients 
were excluded if they had any contraindications to MRI; had any contraindications to olmesartan or 
amlodipine; had severe hypertension (msSBP ≥180 mmHg, msDBP ≥110 mmHg); were pregnant; had 
a history of angioedema; had a history or evidence of a secondary form of hypertension; had 
experienced a transient ischaemic attack (TIA), stroke, myocardial infarction (MI), or peripheral 
artery disease (PAD) requiring intervention in the 12 months prior to screening; had undergone 
percutaneous coronary intervention (PCI); had type 1 diabetes mellitus; or had type 2 diabetes 
mellitus that was not well-controlled with oral medication, or was being treated with insulin. Certain 
concomitant medications were prohibited, including any anti-hypertensive agents (ARBs, ACE-
inhibitors, β-blockers, diuretics) or anti-arrhythmic drugs. Patients who were being treated with a 
statin were required to have been taking the same statin at the same dose for at least 4 weeks prior 
to screening. 
 
Measurements: 
Data were entered into an electronic case report form (eCRF). All patients had their office BP and 
heart rate measured in standard fashion 8 and underwent a 12-lead ECG at rest. At the visit 
immediately prior to initiation of the study drug, a cardiovascular MRI scan was performed in order 
to determine aortic distensibility and LV mass. In addition the Sphygmocor device was used to 
perform pulse wave analysis and pulse wave velocity. The pulse wave assessments and MRI scans 
were performed at baseline and after 12 and 52 weeks of treatment.  
 
MRI Acquisition 
ECG gated MRI was performed at each site on a 3.0 Tesla whole body scanner equipped with cardiac 
phased array coils (Magnetom Trio, Magnetom Skyra, Magnetom Prisma; Siemens Healthineers, 
Germany). After scout imaging and acquisition of a stack of axial Single Shot Turbo Spin Echo (HASTE) 
images of the whole chest cine balanced steady state free precession images (bSSFP) were acquired 
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in the short axis (contiuguous gapless, whole heart), as well as in vertical and horizontal long axes 
views (3 midventricular slices in each orientation) with the following sequence parameters: Slice 
thickness 8 mm, FOV 340x273 mm; In plane resolution 1.5 x 1.5 mm2; Flip angle 50°; Lines per phase 
13; Retrospective ECG gating, 25 calculated phases; Bandwith 970 Hz per pixel; Repetition Time 3 ms; 
Echo time 1.5 ms. Subsequently retrospectively ECG gated axial spoiled gradient recalled echo 
(spGRE) were acquired at the level of the right pulmonary artery and 10 cm below with the following 
sequence parameters: Slice thickness 6mm; Matrix 256x256; FOV 340 x 292 mm2; Spatial resolution 
1.1 x 1.1 mm2; Calculated phases 50; temporal resolution 20 ms; Lines per phase 7; Bandwith 401 Hz 
per pixel; Repetition time 7 ms; Echo time 4 ms. 
 
 
MRI Analysis 
Cine MRI were transferred to a postprocessing server (SyngoVia; Siemens Healthineers, Germany) for 
evaluation of left ventricular mass. Inner and outer contours of the left ventricular myocardium were 
segmented on short axis images, position of aortic and mitral valves on horizonatal and vertical long 
axes. Mass and mass index were calculated as reported previously 28. For aortic distensibility the 
cross-sectional lumen area of the aorta was segmented in systole (Amax) and diastole (Amin) at 
three different locations: In the ascending (ascending aorta) and descending (proximal descending 
aorta) aorta at the level of the right pulmonary artery and 10 cm lower (distal descending aorta). 
Distensibility was calculated as follows: 
 
𝐷𝑖𝑠𝑡𝑒𝑛𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦 [10 − 3 𝑥 𝑚𝑚𝐻𝑔 − 1] =  
Amax − Amin
𝐴𝑚𝑖𝑛 𝑥 (𝑃𝑢𝑙𝑠𝑒 𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒)
𝑥 1000 
 
Pulse Wave analysis and velocity 
The SphygmoCor® XCEL device (AtCor Medical, Sydney Australia) was used to provide a central 
arterial pressure waveform from which central PP, augmentation pressure (AP; added pressure due 
to wave reflection), and augmentation pressure index (AI; % of central PP due to wave reflection) 
were derived. The carotid–femoral pulse wave velocity (PWV), was also measured. Measurements 
were taken in supine position and BP measurements for calibration of the Sphygmocor were taken 
immediately prior to the pulse wave recording.  
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Statistics 
The study primary endpoint was that change from baseline in local distensibility as measured by MRI 
in ascending, proximal descending and distal descending aorta after 52 weeks of treatment. 
Secondary and exploratory endpoints included but not limited to: vascular parameters such as local 
aortic strain, aortic pulse wave velocity, central blood pressure, augmentation index as well as left 
ventricular mass and left ventricular mass index. 
Sample size estimation was based on an observed SD for change from baseline to 52 weeks using 
MRI of 1.08793, 5.63031 and 1.51536 x 10-3 mmHg‐1 in ascending, proximal descending and distal 
descending aorta in an internal study (unpublished data). A 50 patients per arm was considered 
sufficient to allow detecting a treatment difference of 0. 6785 x 10-3 mmHg‐1 mmHg‐1 between the 
two study groups in proximal descending aorta (approximately ½ of the observed SD). This difference 
was considered as clinically relevant. The number of randomized patients was believed appropriate 
to ensure that 100 patients complete 52 weeks of treatment. 
For baseline characteristics, the continuous variables were provided as means with standard 
deviations (SD), while categorical data were presented as absolute values and percentages. 
Statistically significant differences between baseline characteristics were determined using a 
student’s t-test or a chi-squared test, as appropriate. The primary and secondary endpoints were 
analysed using a linear model, with treatment as the fixed effect and the corresponding baseline as a 
covariate. Least squares regression analysis was used to estimate the mean and 95% Confidence 
interval (95% CI) for change from baseline of each variable between the sacubitril/valsartan and 
olmesartan patients. All analysis was performed using the SAS software. 
 
RESULTS 
Study Patients 
A total of 115 patients were enrolled in the study, one of whom was discontinued after 
randomisation. This left 114 patients who received the study medication to which they were 
assigned. The mean age of the population was 59.8 ± 10.7 years and 67.5% were male, with no 
significant differences between the two drug groups (Table 1). The mean SBP was 155.1 ± 9.0 mmHg, 
and the mean DBP was 92.2 ± 8.7 mmHg, with highly similar values in the two groups. Heart rate 
(mean: 70.2 ± 10.3 bpm) and PP (mean: 62.9 ± 9.3 mmHg) also did not differ between the sets of 
patients. LV mass at baseline was not different between the two drug groups (148 ± 46 vs 145 ± 33 g 
and 72.1 ± 18 vs 72.1 ± 12 g/m², respectively). Similar proportions of patients in each group were 
being treated with anti-diabetic drugs and/or statins.  
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Office systolic BP decreased in the sacubitril/valsartan group by - 25.7 and in the Olmesartan group 
by -22.8 mmHg; treatment difference was not statistically significant (-2.58 [95 % CI -7.53 , 2.38] , p = 
0.31) following 12 weeks of treatment. The corresponding systolic BP decreases after 52 weeks were 
26.1 mmHg in the sacubitril/valsartan group and 20.8 mmHg in the Olmesartan group, with a 
significantly greater decrease in the sacubitril/valsartan group (-4.99 [95 % CI -9.46; -0.53], p=0.028). 
After 12 weeks of treatment office diastolic BP decreased in the sacubitril/valsartan group by 11.9 
mmHg and in the olmesartan group by 12.1 mmHg, with no significant difference between the 
groups (0.17 [95 % CI -1.8, +3.2] mmHg, p=0.91. The corresponding values after 52 weeks are -13.5 
mmHg and -12.2 mmHg for the sacubitril/valsartan group and olmesartan group, respectively, 
without any significant difference between the two groups (-1.29 [95% CI -4.2, 1,6] mmHg, p=0.38). 
(Figure 2). During the 40-week add-on period, 17.5% (10 patients) of the sacubitril/valsartan group 
and 29.8% (17 patients) of the olmesartan group received amlodipine (p = 0.12). 
Changes in aortic distensibility 
In the group of patients that were treated with sacubitril/valsartan, the distensibility of the ascending 
aorta increased by 0.22 [95 % CI -0.17;  0.61, p = 0.26]× 10−3 mmHg−1 from baseline to 52 weeks, and 
by 0.30 ([95 % CI -0.31 , 0.92,] p = 0.33]) 0.33 × 10−3 mmHg−1. The treatment difference was 0.12 ([ 95 
% CI -0.35 , 0.60], p = 0.60) (Figure 3). When considering the period from baseline to 12 weeks, the 
corresponding values were (0.66 × 10−3 ([95% CI  0.28; 1.04], p < 0.001) mmHg−1 for the 
sacubitril/valsartan group and 0.56 ([95% CI -0.06; 1.18] p = 0.07 × 10−3 mmHg−1 for the olmesartan 
group (p = 0.60). The treatment difference was -0.53 ([95 % CI -1.18 ; 0.12], p = 0.11).  
In the proximal descending aorta, changes from baseline to 52 weeks were of 0.54 ( [95% CI 0.09 , 
1.01], p =0.025)  × 10−3 mmHg−1 and 0.55 ([95 % CI  -0.10; 1.19), p =0.10) × 10−3 mmHg−1 for 
sacubitril/valsartan and olmesartan, respectively; the treatment difference was -0.08 ([95% CI -0.70; 
0.534] p = 0.79). For the period from baseline to 12 weeks, the values for change from baseline were 
0.58 ([95 % CI 0.12 , 1.03], p= 0.014) × 10−3 mmHg−1 and 1.03 ([95 % CI 0.38 , 1.68], p =0.002) × 10−3 
mmHg−1, for sacubitril/valsartan and olmesartan respectively; treatment difference -0.53 ([95 % CI -
1.18 , 0.12], p = 0.11).  
In the distal descending aorta changes from baseline were 0.37 ([95 % CI -0.38; 1.13], p =0.33) × 10−3 
mmHg−1 and 0.57 ([95 % CI -0.16, 1.30], p =0.13) × 10−3 mmHg−1  at 52 and 12 weeks of treatment in 
the sacubitril/valsartan and were 0.57 ( [95 % CI -0.16 , 1.30], p = 0.13) × 10−3 mmHg−1 and 0.90 ([95 
% CI 0.17; 1.63] p =0.016) × 10−3 mmHg−1 and 52 and 12 weeks of treatment in the olmesartan group. 
No-significant differences were observed in the change from baseline in local distal descending 
distensibility  between sacubitril/valsartan and olmesartan groups at 52 weeks, (treatment difference 
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- 0.08 [95 %  -0.70 , 0.54], p = 0.79) × 10−3 mmHg−1 ) and at 12 weeks (treatment difference -0.25 [95 
% CI -0.92 , 0.42], p = 0.49] × 10−3 mmHg−1 ) (Figure 2). 
 
Changes in left ventricular mass 
LV mass decreased for both groups from baseline to 12 weeks (−11.19 [95 % CI -16.66 ; -5.72]  in the  
sacubitril/valsartan patients vs. −3.28 [ 95 % CI -8.81; 2.04] g) in the olmesartan patients, treatment 
difference was - 8.0966 [95 % CI -15.9848 ; -0.2084] g,  p = 0.049 (Figure 4A). At 52 weeks, reduction 
LV mass reduction were −11.19 [95 % CI -15.05 ; -7.33] g  in the  sacubitril/valsartan patients 
compared to vs. −5.60 [ 95 % CI -9.30; -1.90] g in the olmesartan patients, treatment difference was -
5.1942 [95 % CI -10.65 , 0.26] g,  p = 0.062) (Figure 4A). The mean change from baseline to 52 weeks 
for the sacubitril/valsartan group was similar to the mean change between baseline and 12 weeks, 
while that for the olmesartan group was numerically higher for the longer time period. This resulted 
in the difference between the two groups being borderline statistically significant when comparing 
the 52-week data. 
When the LV mass was adjusted for body surface area (LV mass index), there was, again, a greater 
decrease for the sacubitril/valsartan patients than the olmesartan patients from baseline to 12 weeks 
(treatment difference -4.05 [95 % CI -7.90 , -0.20 g/m²]; p = 0.039) (Figure 4). When comparing the 
changes from baseline to 52 weeks,  a superior decrease in the sacubitril/valsartan patients was also 
observed compared to the olmesartan patients (treatment difference -3.27  [95 % CI -6.21; -0.34] 
g/m²; p = 0.029).  
Importantly, the higher reductions in LV mass and LV mass index with sacubitril/valsartan compared 
to olmesartan were apparent following 12 weeks of treatment when there were no meaningful 
differences in brachial systolic and diastolic as well as central systolic blood pressure. However, since 
systolic (not diastolic) office BP decreased to a greater extent with sacubitril/valsartan following 52 
week of treatment adjustment for attained office SBP at follow-up were made. Nevertheless, the 
differences between the effects of the two drugs on LV mass index remained significant (p = 0.036 
and 0.019 at 12 and 52 weeks, respectively), with sacubitril/valsartan having superior efficacy on LV 
mass reduction. When adjusting for the change in office SBP at 12 and 52 weeks follow-up, the 
differences between two drugs on LV mass index were -3.57 [95 % CI: -7.32, 0.18] g/m² (p=0.0619) 
and -2.80 [95 % CI: -5.63, 0.04] g/m², (p=0.0529), respectively. Taking all the information together, 
our data point to some extent to a blood pressure independent effect of sacubitril/valsartan on LV 
mass reduction. 
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Changes in central pulse wave parameters 
Central SBP and DBP both decreased from baseline to 52 weeks, with no-significant differences 
between the sacubitril/valsartan and olmesartan patients (mean difference: SBP: −3.03 mmHg; 95% 
CI: −7.23, 1.17; p = 0.156; DBP: 0.11 mmHg; 95% CI: −2.85, 3.08; p = 0.939) (Table 2). The decrease in 
central PP was significantly greater in the sacubitril/valsartan group (-6.54 mmHg, 95% CI: -8.4,-4.67) 
compared to the olmesartan group (-3.04 mmHg, 95% CI: -4.91,-1.17) after 52 weeks (mean 
difference: −3.50 mmHg; 95% CI: −6.15, - 0.85; p = 0.010). Other vascular parameters disclosed not 
any significant difference between the two groups (table 2).  
 
DISCUSSION 
The principal finding of our double-blind, randomized study is that in patients with hypertension 
treatment with sacubitril/valsartan resulted in superior reductions in LV mass and central PP at 52 
weeks compared to treatment with olmesartan. Reductions in LV hypertrophy has been shown to be 
associated with an improvement in outcome and to reduce the risk of CV morbidity and mortality 8, 9 
significantly decreased CV risk and represents a therapeutic target of antihypertensive therapy 8. 
Thus, these data indicate clinical benefits of the dual-acting ARB and neprilysin inhibitor, 
sacubitril/valsartan.  
The importance of LV mass as a treatment target in patients with hypertension has been 
demonstrated in a number of studies. Koren et al. reported higher rates of CV events, CV death, and 
all-cause mortality for hypertensive patients with a high compared to a low LV mass 9. Similarly, 
Muiesan et al. found that the proportion of patients that experienced a CV event increased with 
increased LV mass index, and that persistence of LVH during antihypertensive treatment was an 
independent predictor of CV events 10. In the LIFE study, independent of treatment modality and BP 
control, LV mass index reduction was associated with a lower risk of the combined endpoint of CV 
death, stroke, and MI 29. In another study, Mathew et al. linked LVH regression during treatment with 
an ACE-inhibitor to decreased risk of CV death, MI, and heart failure 30. Finally, in a meta-analysis 
reduction of LV mass was associated with improved cardiovascular prognosis 30.  
Office SBP was reduced to a greater extent on treatment with sacubitril/valsartan compared to 
olmesartan. This is in agreement with previous studies, which have shown sacubitril/valsartan to be 
superior to valsartan for BP lowering in patients with hypertension 31, 32. In the present study, the 
greater reduction in LV mass index for the sacubitril/valsartan group compared to the olmesartan 
group was already observed after 12 weeks of treatment, at similar changes in brachial systolic and 
diastolic BP. It remained significant at 12 and 52 weeks of treatment when adjusted for office SBP 
Page 12 of 26 
 
during follow up, with a similar signal when adjusted for the difference in change of systolic BP. 
These analysis indicate that the difference in LV mass reduction cannot be attributed to differences 
in BP alone thereby suggesting that the dual inhibitor may exert beneficial effects beyond those 
attributable to decreases in BP. In the Losartan Intervention for Endpoint Reduction in Hypertension 
(LIFE) trial, a larger decrease in LV mass was found for the patients being treated with losartan in 
comparison to those being treated with the beta-blocker, atenolol, while BP control did not differ 
greatly between the two groups 13. The RAS has been previously linked to LVH in patients with 
hypertension, with higher levels of angiotensin II associated with greater LV mass the independent of 
24 hour ambulatory BP 33.  Furthermore, in a meta-analysis evaluating the effects of different 
antihypertensive drugs, treatment with ACE-inhibitors and ARBs, resulted in greater decreases in LV 
mass than did diuretics and beta-blockers 14. Now, we observed that beyond BP reduction and RAS 
inhibition the dual inhibitor sacubitril/valsartan exerts additional effects on LV mass reduction.  
It has been hypothesised that the vasodilatory and anti-proliferative effects of the neprilysin-
inhibitor moiety of sacubitril/valsartan may provide additional benefits to those of the RAS-inhibitor 
component, further reducing the risks associated with LV remodelling. In the PARADIGM-HF trial, 
larger reductions in the composite endpoint of CV death and heart failure hospitalisation, CV death 
and death from any cause were observed for sacubitril/valsartan treatment compared to enalapril 
treatment in heart failure patients with a reduced ejection fraction 26. The study did not provide 
further insight with pathogenetic mechanisms caused the improved cardiovascular outcome. Our 
data in a different population, namely hypertensive patients, support the hypothesis that reduction 
in LV mass may be one of the predominant mechanisms by which the lower incidence of CV events 
was caused in the PARADIGM-HF Study 26. Nevertheless, a prospective double blind prospective 
study is needed to allow conclusive evidence on the cardioprotective effects of sacubitril/valsartan in 
a hypertensive population, with repeated measurements of LV mass.  
In the present analysis, local distensibility was not found to differ between the two treatment 
groups. Numerically an increase of local distensibility was observed, but the effect seen was too 
small to reach statistical significance. Nevertheless, the larger decrease in central PP in the 
sacubitril/valsartan (compared to the olmesartan) patients indicates that global distensibility was 
improved. Amlodipine having preventing effects on the progression of arterial stiffness 34 was added 
in both treatments, but numerically more frequently in the olmesartan group thereby if any 
minimizing the difference of central PP between the two groups. Our data are supported by the 
PARAMETER study that was conducted in parallel to our study 35. In this elderly hypertensive 
population treatment with sacubitril/valsartan demonstrated superiority in reducing central active 
pressure (primary objective) versus treatment with olmesartan 35. In accordance, treatment with 
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omapatrilat vasopeptase inhibitor reduced pulse pressure and aortic stiffness to greater extent in 
patients with systolic hypertension than the comparator enalapril 24. Thus, improved aortic stiffness 
that leads to unloading of the LV may have contributed to the greater decrease in LV mass observed 
for the sacubitril/valsartan group compared to the olmesartan group.  
It is interesting to note that the effects of the two drugs on LV mass did not increase over time. Data 
collected 12 weeks after treatment initiation, prior to the add-on period, generally showed already 
significant decreases in LV mass when compared to the period from baseline to 52 weeks. The 
reductions in central SBP and DBP were almost the same for the period from baseline to 12 weeks 
and from baseline to 52 weeks, indicating that the initial antihypertensive effect was sustained, but 
did not increase over time.  
 
Limitations 
One limitation to this study is that MRI scans were only taken at three time points. This prevented us 
from analysing changes in vascular and ventricular modelling over time. A further drawback was the 
absence of peripheral biomarker analysis. This may have helped to elucidate the mechanisms by 
which the improvements in LV mass and distensibility were achieved. As adverse events were 
grouped according to treatment period rather than time, it is not possible to determine how the 
changes in therapy affected their frequency.  
 
CONCLUSIONS 
The hypertensive patients treated with sacubitril/valsartan displayed greater reductions in LV mass 
compared to those treated with olmesartan after 12 and 52 weeks of treatment. The observed 
difference in the change of LV mass cannot be attributed to minor differences in BP response. This 
suggests that the drug may exert beneficial effects on CV remodelling that go beyond that caused by 
BP reduction.  
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FIGURE LEGEND   
Figure 1: Trial design 
 
Figure 2: Changes in systolic and diastolic BP from baseline 
A: Changes in systolic BP from baseline 
B: Changes in diastolic BP from baseline  
 (Please note that after 12 weeks amlodipine treatment was added in 10 patients of the 
sacubitril/valsartan group vs. 17 patients in the olmesartan group [p=0.12]).  
Precise p-values are given for the comparison between the two groups;  
*p<0.05, **p<0.01, ***p<0.01 vs baseline 
Mean ± 95 % CI are given 
 
Figure 3: Changes in local aortic distensibility from baseline:  
A) Changes from baseline to 12 weeks; B) Changes from baseline to 52 weeks.  
Precise p-values are given for the comparison between the two groups;  
*p<0.05, **p<0.01, ***p<0.01 vs baseline  
Mean ± 95 % CI are given 
 
Figure 4: Changes in left ventricular mass from baseline  
A) Changes in least squares mean left ventricle mass from baseline; B) changes in least squares mean 
left ventricle mass index from baseline. Error bars represent standard error of the mean. 
Precise p-values are given for the comparison between the two groups;  
*p<0.05, **p<0.01, ***p<0.01 vs baseline 
Mean ± 95 % CI are given 
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Table 1: Patient characteristics of the two groups 
 Sacubitril/valsarta
n 
N = 57 
Olmesartan 
N = 57 
 P value  
at baseline      
Age (years, mean ± SD) 60.5 ± 7.8 59.2 ± 13.1  0.53  
Gender (male N(%)) 37 (64.9) 40 (70.2)  0.55  
BMI (kg/m2, mean ± SD) 28.1 ± 4.5 28.6 ± 3.9  0.52  
SBP (mmHg, mean ± SD) 155.3 ± 9.0 155.0 ± 9.1  0.88  
 Median (mmHg) 154 156    
 Min-Max (mmHg) 136-179 139-178    
DBP (mmHg, mean ± SD) 92.7 ± 8.8 91.7 ± 8.7  0.54  
 Median (mmHg)  93 92    
 Min-Max (mmHg) 68-107 69-110    
Heart rate (bpm, mean ± SD) 69.9 ± 9.4 70.5 ± 11.2  0.75  
 Median (bpm)  70 70    
 Min-Max (bpm) 49-92 46-100    
Pulse pressure (mmHg, mean ± SD) 62.6 ± 8.9 63.3 ± 9.7  0.82  
 Median (mmHg)  62 63    
 Min-Max (mmHg) 50-87 44-89    
Antidiabetic drug use (N(%)) 4 (7.0)  5 (8.8)  0.72  
Statin use (N(%)) 7 (12.3) 7 (12.3)  1.0  
at 12 weeks      
SBP (mmHg, mean ± SD) 129.9 ± 12.5 132.2 ± 14.2  0.31  
 Median (mmHg)  128.5 132    
 Min-Max (mmHg) 106-155 104-162    
DBP (mmHg, mean ± SD) 81.1 ± 8.8 80.2 ± 9.0  0.91  
 Median (mmHg)  80 80    
 Min-Max (mmHg) 58-105 64-103    
HR (bpm, mean ± SD) 69.0 ± 9.58 68.8 ± 12.1  0.80  
 Median (bpm)  69.0 68.0    
 Min-Max (bpm) 50-99 50-97    
at 52 weeks      
SBP (mmHg, mean ± SD) 129.4 ± 11.3 134 ± 12.8  0.03  
 Median (mmHg)  129.4 134.0    
 Min-Max (mmHg) 105-162 107-168    
DBP (mmHg, mean ± SD) 79.1 ± 7.8 79.9 ± 9.2  0.38  
 Median (mmHg) 79.0 79.0    
 Min-Max (mmHg) 59-93 63-115    
HR (bpm, mean ± SD) 69.8 ± 9.0 68.9 ± 11.4  0.38  
 Median (bpm)  70 69    
 Min-Max (bpm) 50-96 49-95    
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Legend: Safety analysis set. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. All comparison from baseline to week 12 and to week 52 were significant (all p<0.001). 
Differences between treatment groups were not statistically significant. 
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Table 2: Change in central hemodynamic parameters   
 Baseline to 12 weeks Baseline to 52 weeks 
 Sacubitril/valsartan 
(N = 53) 
Olmesartan 
(N = 53) 
 Sacubitril/valsartan 
(N = 50) 
Olmesartan 
(N = 50) 
 
 Adjusted LS mean ± SE Difference (95% CI) Adjusted LS mean ± SE Difference (95% CI) 
Central SBP (mmHg) −17.99 ± 1.47 −17.14 ± 1.47 −0.84 (−4.97, 3.28) −16.66 ± 1.50*** −13.63 ± 1.50*** −3.03 (−7.23, 1.17) 
Central DBP (mmHg) −11.44 ± 1.05 −11.08 ± 1.05 −0.37 (−3.31, 2.57) −10.32 ± 1.06*** −10.43 ± 1.06*** 0.11 (−2.85, 3.08) 
Central pulse pressure (mmHg) −6.70 ± 0.88 −5.89 ± 0.88 −0.81 (−3.29, 1.66) −6.54 ± 0.94*** −3.04 ± 0.94* −3.50 (−6.15, 0.85)+ 
Central AP (mmHg) −2.46 ± 0.53 −2.93 ± 0.53 0.47 (−1.04, 1.98) −2.44 ± 0.60*** −1.44 ± 0.60 −1.01 (−2.69, 0.67) 
Central AI (%) −1.94 ± 1.13 −4.53 ± 1.13 2.60 (−0.64, 5.83) −2.39 ± 1.18* −1.52 ± 1.18 −0.87 (−4.22, 2.48) 
HR-corrected central AI (%) −2.41 ± 1.03 −4.09 ± 1.03 1.69 (−1.24, 4.61) −2.17 ± 1.13* −1.63 ± 1.13 −0.55 (−3.75, 265) 
Carotid–femoral PWV (m/s) −0.98 ± 0.13 −0.82 ± 0.13 −0.17 (−0.53, 0.20) −0.43 ± 0.17* −0.43 ± 0.17* 0.01 (−0.46, 0.47) 
Legend: *p<0.05, **p<0.01, ***p<0.01 vs baseline; +p = 0.010 vs olmesartan; all other comparisons were not statistically significant (p > 0.05). LS, least squares; 
SE, standard error; SBP, systolic blood pressure; DBP, diastolic blood pressure; AP, augmentation pressure; AI, augmentation index; HR, heart rate; PWV, pulse 
wave velocity. 
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Figures 
Figure 1: Trial design 
 
Legend: QD, once-daily; BP, blood pressure.
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Figure 2: Changes in BP from baseline 
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Figure 3: Changes in local aortic distensibility from baseline 
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Figure 4: Changes in left ventricular mass from baseline 
 
 
